BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schneider EK, Reyes-Ortega F, Li J, Velkov T. Can Cystic Fibrosis Patients Finally Catch a Breath With Lumacaftor/Ivacaftor? Clin Pharmacol Ther 2017;101:130-41. [PMID: 27804127 DOI: 10.1002/cpt.548] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Ghelani DP, Schneider-Futschik EK. Emerging Cystic Fibrosis Transmembrane Conductance Regulator Modulators as New Drugs for Cystic Fibrosis: A Portrait of in Vitro Pharmacology and Clinical Translation. ACS Pharmacol Transl Sci 2020;3:4-10. [PMID: 32259083 DOI: 10.1021/acsptsci.9b00060] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
2 Bulloch MN, Hanna C, Giovane R. Lumacaftor/ivacaftor, a novel agent for the treatment of cystic fibrosis patients who are homozygous for the F580del CFTR mutation. Expert Rev Clin Pharmacol 2017;10:1055-72. [PMID: 28891346 DOI: 10.1080/17512433.2017.1378094] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
3 Michaels WE, Bridges RJ, Hastings ML. Antisense oligonucleotide-mediated correction of CFTR splicing improves chloride secretion in cystic fibrosis patient-derived bronchial epithelial cells. Nucleic Acids Res 2020;48:7454-67. [PMID: 32520327 DOI: 10.1093/nar/gkaa490] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
4 Schneider-Futschik EK. Beyond cystic fibrosis transmembrane conductance regulator therapy: a perspective on gene therapy and small molecule treatment for cystic fibrosis. Gene Ther 2019;26:354-62. [PMID: 31300729 DOI: 10.1038/s41434-019-0092-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
5 Abdallah K, De Boeck K, Dooms M, Simoens S. A Comparative Analysis of Pricing and Reimbursement of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Europe. Front Pharmacol 2021;12:746710. [PMID: 34858177 DOI: 10.3389/fphar.2021.746710] [Reference Citation Analysis]
6 Qiu F, Habgood M, Schneider-Futschik EK. The Balance between the Safety of Mother, Fetus, and Newborn Undergoing Cystic Fibrosis Transmembrane Conductance Regulator Treatments during Pregnancy. ACS Pharmacol Transl Sci 2020;3:835-43. [PMID: 33073185 DOI: 10.1021/acsptsci.0c00098] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
7 Vonk SEM, van der Meer-Vos M, Bos LDJ, Neerincx AH, Majoor CJ, Maitland-van der Zee AH, Mathôt RAA, Kemper EM; Amsterdam Mucociliary Clearance Disease (AMCD) research group. Quantitative Method for the Analysis of Ivacaftor, Hydroxymethyl Ivacaftor, Ivacaftor Carboxylate, Lumacaftor, and Tezacaftor in Plasma and Sputum Using Liquid Chromatography With Tandem Mass Spectrometry and Its Clinical Applicability. Ther Drug Monit 2021;43:555-63. [PMID: 33165217 DOI: 10.1097/FTD.0000000000000829] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Yang Z, Hildebrandt E, Jiang F, Aleksandrov AA, Khazanov N, Zhou Q, An J, Mezzell AT, Xavier BM, Ding H, Riordan JR, Senderowitz H, Kappes JC, Brouillette CG, Urbatsch IL. Structural stability of purified human CFTR is systematically improved by mutations in nucleotide binding domain 1. Biochim Biophys Acta Biomembr 2018;1860:1193-204. [PMID: 29425673 DOI: 10.1016/j.bbamem.2018.02.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
9 Reyes-Ortega F, Qiu F, Schneider-Futschik EK. Multiple Reaction Monitoring Mass Spectrometry for the Drug Monitoring of Ivacaftor, Tezacaftor, and Elexacaftor Treatment Response in Cystic Fibrosis: A High-Throughput Method. ACS Pharmacol Transl Sci 2020;3:987-96. [PMID: 33073196 DOI: 10.1021/acsptsci.0c00103] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Bergbower E, Boinot C, Sabirzhanova I, Guggino W, Cebotaru L. The CFTR-Associated Ligand Arrests the Trafficking of the Mutant ΔF508 CFTR Channel in the ER Contributing to Cystic Fibrosis. Cell Physiol Biochem 2018;45:639-55. [PMID: 29402832 DOI: 10.1159/000487120] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
11 Schneider EK. Cytochrome P450 3A4 Induction: Lumacaftor versus Ivacaftor Potentially Resulting in Significantly Reduced Plasma Concentration of Ivacaftor. Drug Metab Lett 2018;12:71-4. [PMID: 29595119 DOI: 10.2174/1872312812666180328105259] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 7.7] [Reference Citation Analysis]
12 Tan M, Reyes-ortega F, Schneider-futschik EK. Successes and Challenges: Inhaled Treatment Approaches Using Magnetic Nanoparticles in Cystic Fibrosis. Magnetochemistry 2020;6:25. [DOI: 10.3390/magnetochemistry6020025] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
13 Garaci E. From thymus to cystic fibrosis: the amazing life of thymosin alpha 1. Expert Opin Biol Ther 2018;18:9-11. [PMID: 30063868 DOI: 10.1080/14712598.2018.1484447] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
14 Marson FAL, Bertuzzo CS, Ribeiro JD. Personalized or Precision Medicine? The Example of Cystic Fibrosis. Front Pharmacol 2017;8:390. [PMID: 28676762 DOI: 10.3389/fphar.2017.00390] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 6.2] [Reference Citation Analysis]
15 Yamada A, Komaki Y, Komaki F, Micic D, Zullow S, Sakuraba A. Risk of gastrointestinal cancers in patients with cystic fibrosis: a systematic review and meta-analysis. Lancet Oncol. 2018;19:758-767. [PMID: 29706374 DOI: 10.1016/s1470-2045(18)30188-8] [Cited by in Crossref: 64] [Cited by in F6Publishing: 28] [Article Influence: 16.0] [Reference Citation Analysis]
16 Tan M, Reyes-ortega F, Schneider-futschik EK. Magnetic Nanoparticle-Based Drug Delivery Approaches for Preventing and Treating Biofilms in Cystic Fibrosis. Magnetochemistry 2020;6:72. [DOI: 10.3390/magnetochemistry6040072] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Allobawi R, Ghelani DP, Schneider-Futschik EK. Metabolomic Description of Ivacaftor Elevating Polymyxin B Mediated Antibacterial Activity in Cystic Fibrosis Pseudomonas aeruginosa. ACS Pharmacol Transl Sci 2020;3:433-43. [PMID: 32566909 DOI: 10.1021/acsptsci.0c00030] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
18 Cremers S, Aronson JK. Drugs for rare disorders. Br J Clin Pharmacol 2017;83:1607-13. [PMID: 28653488 DOI: 10.1111/bcp.13331] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
19 Talwalkar JS, Koff JL, Lee HB, Britto CJ, Mulenos AM, Georgiopoulos AM. Cystic Fibrosis Transmembrane Regulator Modulators: Implications for the Management of Depression and Anxiety in Cystic Fibrosis. Psychosomatics 2017;58:343-54. [PMID: 28576305 DOI: 10.1016/j.psym.2017.04.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
20 Matos AM, Gomes-Duarte A, Faria M, Barros P, Jordan P, Amaral MD, Matos P. Prolonged co-treatment with HGF sustains epithelial integrity and improves pharmacological rescue of Phe508del-CFTR. Sci Rep 2018;8:13026. [PMID: 30158635 DOI: 10.1038/s41598-018-31514-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
21 Harwood KH, McQuade RM, Jarnicki A, Schneider-Futschik EK. Anti-Inflammatory Influences of Cystic Fibrosis Transmembrane Conductance Regulator Drugs on Lung Inflammation in Cystic Fibrosis. Int J Mol Sci 2021;22:7606. [PMID: 34299226 DOI: 10.3390/ijms22147606] [Reference Citation Analysis]
22 Walayat S, Hussain N, Patel J, Hussain F, Patel P, Dhillon S, Aulakh B, Chittivelu S. Drug-induced dyspnea versus cystic fibrosis exacerbation: a diagnostic dilemma. Int Med Case Rep J 2017;10:243-6. [PMID: 28769592 DOI: 10.2147/IMCRJ.S139022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
23 Hanafin PO, Sermet-Gaudelus I, Griese M, Kappler M, Ellemunter H, Schwarz C, Wilson J, Tan M, Velkov T, Rao GG, Schneider-Futschik EK. Insights Into Patient Variability During Ivacaftor-Lumacaftor Therapy in Cystic Fibrosis. Front Pharmacol 2021;12:577263. [PMID: 34408649 DOI: 10.3389/fphar.2021.577263] [Reference Citation Analysis]
24 Schneider-futschik EK, Lobert VH, Wilson JW. Editorial: Functional Characterization and Pharmaceutical Targets in Common and Rare CFTR Dysfunctions. Front Physiol 2022;12:830285. [DOI: 10.3389/fphys.2021.830285] [Reference Citation Analysis]